A Vascular Permeability Assay Using An *In Vitro* Human Microvessel Model Mimicking The Inflammatory Condition

Joris Pauty [a,b], Ryo Usuba [a], Haruko Takahashi [a], Junichi Suehiro [c], Kanoko Fujisawa [a], Kiichiro Yano [d], Tomohiro Nishizawa [d], Yukiko T. Matsunaga [a,b,*]

[a] Center for International Research on Integrative Biomedical Systems (CIBiS), Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan

[b] LIMMS/CNRS-IIS (UMI 2820), Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan

[c] Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo 181-8611, JAPAN

[d] End-Organ Disease Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan

* Address correspondence to mat@iis.u-tokyo.ac.jp

Supplementary materials

Content:

1. Supplementary method: Immunofluorescence of ZO-1 on a 2D model

2. Figure S1: Immunofluorescence on 2D model showing the effect of the treatments on the tight junctions and actin cytoskeleton

1. Supplementary method

Immunofluorescence of ZO-1 on a 2D model

The primary antibody targeting ZO-1 (Rabbit pAb, 40-2200) was purchased from Life Technologies - Thermo Fisher Scientific, Co. (Waltham, MA, USA). Immunofluorescence was performed as described in the Materials and Methods section of the manuscript with a dilution 1:100 of the primary antibody.

2. Supplementary Figure



Figure S1. Immunofluorescence on 2D model showing the effect of the treatments on the tight junctions and actin cytoskeleton

(A, B) Immunofluorescence of ZO-1(green), actin cytoskeleton (red) and nucleus (blue) on the 2D-model treated the same way as the microvessel model; scale bars: 20 µm. (A) ZO-1 and actin cytoskeleton in absence of treatment. (B) *Left*: effect of 30-min incubation with 10 mM EDTA followed by 60-min incubation with EGM-2; *middle and right*: effect of 30-min treatment with 100 U/mL thrombin after pre-treament with EDTA and incubation with EGM-2 or 200 µM 007.